Abstract
Thrombotic microangiopathy (TMA) in renal transplantation (RTX) generally develops during treatment with calcineurin inhibitors. We present a RTX case that developed TMA under everolimus treatment. A 40-year-old woman received a kidney allograft from her 77-year-old mother. She initially received tacrolimus, mycophenolate mofetil and steroids. She was discharged with a creatinine level of 2.2 mg/dl after treatment for a cellular rejection attack within the first two weeks after transplantation. Later on, tacrolimus was replaced with everolimus. One year later, she presented with fever and increased creatinine level (4 mg/dl), anemia and thrombocytopenia. Her peripheral blood smear revealed signs of microangiopathic hemolysis. Bone marrow examination revealed an increased number of megakaryocytes. We diagnosed the case as TMA and initiated plasma exchange, I.V. pulse steroid treatment and stopped everolimus. This approach improved laboratory and clinic abnormalities. The development of TMA after treatment with everolimus and the exclusion of other possible causes suggested TMA associated with proliferating signal inhibitors (PSIs) in our case.
References
Manzoor K, Ahmed E, Akhtar F et al (2006) Cyclosporine withdrawal in post-renal transplant thrombotic microangiopathy. Clin Transpl 20:43–44
Ponticelli C, Banfi G (2006) Thrombotic microangiopathy after kidney transplantation. Transpl Int 19:789–792
Schwimmer J, Nadasdy TA, Spitalnik PF et al (2003) Denovo thrombotic microangiopathy in renal transplant recipients: a comparison of hemolytic uremic syndrome with localized renal thrombotic microangiopathy. Am J Kidney Dis 41:471–473
Ardalan MR (2006) Review of thrombotic microangiopathy (TMA), post-renal transplant TMA. Saudi J Kidney Dis Transpl 17:235
Pelle G, Xu Y, Khoury N et al (2005) Thrombotic microangiopathy in marginal kidneys after sirolimus use. Am J Kidney Dis 46:1124
Couriel DR, Saliba R, Escalon MP et al (2005) Sirolimus in combination with tacrolimus, corticosteroids for the treatment of resistant chronic graft-versus-host disease. Br J Hematol 130:409
Sartelet H, Toupance O, Lorenzato M et al (2005) Sirolimus-induced thrombotic microangiopathy is associated with decreased expression of vascular endothelial growth factor in kidneys. Am J Transp 5:2441
Yango A, Morrissey P, Monaco A et al (2002) Successful treatment of tacrolimus-associated thrombotic microangiopathy with sirolimus conversion, plasma Exchange. Clin Nephrol 58:77
Mohsin N, Nooyi C, Jha A, Budruddin M, Kamble P, Khalil M et al (2007) Retinal injury as an early manifestation of posttransplant thrombotic microangiopathy: recovery with plasma exchanges and conversion to sirolimus–case report and review of the literature. Transp Proc 39(4):1272–1275
Copelovitch L, Kaplan BS (2008) The thrombotic microangiopathies. Pediatr Nephrol 23(10):1761–1767
Levandovsky M, Harvey D, Lara P, Wun T (2008) Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS): a 24-Year clinical experience with 178 patients. J Hematol Oncol 1(1):23
Chiurchiu C, Ruggenenti P, Remuzzi G (2002) Thrombotic microangiopathy in renal transplantation. Ann Transp 7(1):28–33
Vogelbacher R, Wittmann S, Braun A, Daniel C, Hugo C (2007) The mTOR inhibitor everoimus induces proteinuria and renal deterioration in the remnant kidney model in the rat. Transplantation 84(11):1492–1499
Alexandru S, Ortiz A, Baldovi S, Milicua JM, Ruiz-Escribano E, Eqido J et al (2008) Severe everolimus associated pneumonitis in a renal transplant recipient. Nephrol Dial Transp 23(10):3353–3355
Daniel C, Renders L, Aman K, Schulze-Lohoff E, Hauser IA, Hugo C (2005) Mechanisms of everolimus-induced glomerulosclerosis after glomerular injury in the rat. Am J Transp 5(12):2849–2861
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yılmaz, V.T., Koçak, H., Avcı, A.B. et al. Thrombotic thrombocytopenic purpura associated with everolimus use in a renal transplant patient. Int Urol Nephrol 43, 581–584 (2011). https://doi.org/10.1007/s11255-010-9755-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11255-010-9755-2